Interpace Biosciences Announces First Quarter 2021 Financial and Business Results

May 11, 2021

Interpace Biosciences Announces Improved Coverage for ThyGeNEXT® and ThyraMIR®

May 3, 2021

Interpace Biosciences to Explore Strategic Alternatives for Maximizing Shareholder Value

Apr 22, 2021

Interpace Biosciences Raises Full Year 2021 Revenue Guidance

Apr 19, 2021

Interpace Pharma Solutions Announces New Advanced Offering in RNA Biomarker Analysis

Apr 12, 2021

Interpace Biosciences Announces New PLA Code and Medicare Reimbursement Increase for Proprietary Thyroid Assay, ThyGeNEXT®

Apr 5, 2021

Interpace Biosciences Announces Full Year and Fourth Quarter 2020 Financial and Business Results

Mar 31, 2021

Interpace Biosciences Announces Divestiture of New Haven CLIA lab to DiamiR

Mar 17, 2021

Interpace Biosciences and XIFIN Forge Strategic Partnership to Improve Financial Performance

Mar 9, 2021

Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Illinois

Feb 25, 2021